Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart stent study halted early: can a pressure wire improve outcomes?

NCT ID NCT02797561

Knowledge-focused Sponsor: Seung-Jung Park Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at using a special wire that measures blood pressure inside heart arteries (called FFR) to help doctors decide which blockages to treat with stents. It included 438 people with two or more blockages in the same artery. The study was stopped early, so the results are not complete, but the goal was to see if FFR guidance reduces heart-related deaths, heart attacks, or the need for repeat procedures.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Fractional flow reserve (FFR) measurement during stent placement
What this could lead to
If successful, this could show that FFR guidance helps doctors decide which blockages to treat, potentially reducing heart attacks and repeat procedures.
What could go wrong
The study was terminated early, so results are limited. It was observational, not a randomized trial, so it cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

438 people

The number who actually took part.

Started

Jul 2016

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

patients with tandem lesion evaluated by FFR

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Tandem lesion evaluated by FFR * Written consent Exclusion Criteria: * TIMI flow \< 3 * Grafted vessel * Left ventricular ejection fraction \< 30% * Severe calcification and/or severe tortuosity * Uncontrolled coronary spasm * Life expectancy \< 2 years * Planned high risk surgery * Pregnancy or breast-feeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary artery disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Percutaneous transluminal coronary angioplasty

Contacts and locations

Locations

  • Asan Medical Center

    Seoul, Songpa-gu, 138-736, South Korea

  • Bundang CHA Hospital

    Seongnam, South Korea

  • Chungnam National University Hospital

    Daejeon, South Korea

  • Daegu Catholic University Medical Center

    Daegu, South Korea

  • Gangwon National Univ. Hospital

    Chuncheon, South Korea

  • Inje University Ilsan Paik Hospital

    Ilsan, South Korea

  • Keimyung University Dongsan Medical Center

    Daegu, South Korea

  • Pusan National University Yangsan Hospital

    Yangsan, South Korea

  • Seoul National University Bundang hospital

    Seongnam, South Korea

  • Seoul National University hospital

    Seoul, South Korea

  • Soon Chun Hyang University Hospital Bucheon

    Bucheon-si, South Korea

  • Wonju Severance Christian Hospital

    Wŏnju, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.